← Back to patent-cliff list
Thiotepa (Shorla Oncology)
Tier C — Watch / tradeThiotepa (Shorla Oncology)
Shorla Pharma Ltd
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DNA
Brand：TEPYLUTE
Indications (approved)：Ovarian cancer, Breast cancer
Regional status
US
Approved
2024-06-25
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Thiotepa (Shorla Oncology)?
Approved indications include: Ovarian cancer, Breast cancer.
When does the Thiotepa (Shorla Oncology) patent expire?
No public expiry year is available for Thiotepa (Shorla Oncology) yet; this page updates once verified.
How do I get a quote for Thiotepa (Shorla Oncology) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27